血液灌流治疗对过敏性紫癜患儿血清IL-23及IL-17水平的影响及意义

目的 探讨血液灌流治疗对过敏性紫癜(HSP)患儿血清白介素(IL)17和IL-23水平的影响及临床意义。方法 选取2011年1月至2012年12月诊断为HSP的患儿87例为病例组,所有患儿均行血液灌流治疗;另选取27例健康儿童为对照组。采用ELISA法检测HSP患儿治疗前后及对照组血清IL-17和IL-23的水平。结果 HSP患儿治疗前血清IL-23及IL-17水平均明显高于对照组(P< 0.05);HSP患儿治疗后血清IL-23及IL-17水平较治疗前均显著降低(P< 0.05),与对照组比较差异无统计学意义(P> 0.05)。HSP患儿血清IL-23与IL-17表达水平呈正相关(P< 0.05)。结论 IL-23和IL-17可能同时参与了HSP的发病过程。血液灌流治疗可以有效降低HSP患儿血清IL-23、IL-17水平,是有效的治疗HSP的方法之一。

Effects of hemoperfusion treatment on serum IL-23 and IL-17 levels in children with Henoch-Schönlein purpure

Objective To study the effects of hemoperfusion treatment on serum interleukin-17 (IL-17) and IL-23 levels in children with Henoch-Schönlein purpura (HSP). Methods Eighty-seven children who were diagnosed with HSP and who had received hemoperfusion treatment between January 2011 and December 2012 were enrolled. Twenty-seven sex- and age-matched healthy children were recruited as normal controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of IL-17 and IL-23. Results The serum IL-23 and IL-17 levels in the HSP group were significantly higher than in the control group (P< 0.05). After hemoperfusion treatment, the serum IL-23 and IL-17 levels in the HSP group were significantly reduced to the levels of the control group. Serum serum IL-17 level was positively correlated with serum IL-23 level (P< 0.05) in children with HSP. Conclusions Hemoperfusion treatment can reduce serum IL-23 and IL-17 levels in children with HSP, suggesting that the treatment may be effective for HSP.